About GEP-NET Patients

Identifying Patients for LUTATHERA

Choose early LUTATHERA for your patients who are newly diagnosed or have progressed on an SSA^1-3

LUTATHERA (lutetium Lu 177 dotatate) can be used to treat SSTR+ GEP-NETs in the foregut, midgut, and hindgut¹

Identifying Patients for LUTATHERA Therapy

Sandy Kotiah, MD, shares her perspectives on identifying eligible patients for LUTATHERA therapy.

LUTATHERA is for patients with newly diagnosed GEP-NETs^1,3

Consider these characteristics

Consider these characteristics for patients with newly diagnosed GEP-NETs: a diagnosis of well-differentiated, SSTR+, metastatic or locally advanced, inoperable GEP-NETs; who are newly diagnosed (within the last 6 months); with a Ki-67 index ≥10% and ≤55% and marked as grade 2 or 3; any GEP-NET primary site; and a Karnofsky Performance Score ≥60.

LUTATHERA is for patients with GEP-NETs after SSA progression^1,2

Consider these characteristics

Consider these characteristics for patients with GEP-NETs after SSA progression: a diagnosis of well-differentiated, SSTR+, metastatic or locally advanced, inoperable GEP-NETs; who have had any prior disease progression while on an SSA; with a Ki-67 index ≤20% and marked as grade 1 or 2; any GEP-NET primary site; and a Karnofsky Performance Score ≥60.

Quote: "LUTATHERA is a therapy option for patients with newly diagnosed, SSTR-positive GEP-NETs and GEP-NETs following progression on somatostatin analogues." Dr. Sandy Kotiah, MD, PhD. Director, The Neuroendocrine Tumor Center at Mercy Medical Center in Baltimore, MD

Which of your patients is ready to start strong with LUTATHERA?

See efficacy data for both patient types

1L, first line; 2L, second line; 3L, third line; GEP-NETs, gastroenteropancreatic neuroendocrine tumors; SSA, somatostatin analogue; SSTR+, somatostatin receptor-positive.

Next page: Efficacy Across Clinical Trials

References: 1. Lutathera. Prescribing information. Novartis Pharmaceuticals Corp. 2. Strosberg J, El-Haddad G, Wolin E, et al; for the NETTER-1 trial investigators. Phase 3 trial of ¹⁷⁷Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125-135. 3. Singh S, Halperin D, Myrehaug S, et al. [¹⁷⁷Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-diﬀerentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403(10446):2807-2817.